Development In Vitro and Biological Evaluation of Chitosan Reinforced Eudragit？？ RL 100 Nanoparticles for the Improvement of Ocular Bioavailability of Acetazolamide

Purpose of present study was to increase topical ocular bioavailability of Acetazolamide. Chitosan reinforced Eudragit？ RL 100 nanoparticles were prepared by Nanoprecipitation Method with slight modifications. Particles Size and Zeta Potential were measured by Malvern Zetasizer, Surface Morphology was done by TEM, Drug Interaction was checked by FTIR spectroscopy, Entrapment Efficiency was determined by Centrifugation Technique, In Vitro Drug Release Study was done by using Franz Diffusion Cell, Intra Ocular Pressure lowering potential was measured in Normotensive Rabbits by using standardized Riester Tonometer. Short Term stability study was done. Particle Size measured was between 92.32±4.65 to 110±4.12 nm, all the formulations were cationic in nature and almost spherical in shape, no any interaction between drug to polymer was seen. Entrapment Efficiency was between 67.3±1.4 to 68.3±2.2 %. Drug Release was recorded for 8 hrs which means sustained delivery was achieved. The IOP lowering potential of plain drug solution in rabbit’s eye was significantly lower than Eudragit Nanoparticles (P<0.001), which in turn was significantly lower than Chitosan reinforced Eudragit Nanoparticles (P<0.001). Formulations were stable for 6 months. Addition of Chitosan in Eudragit Nanoparticles increased the Intra Ocular Pressure lowering effect due to its penetration enhancing power